The continuing role of PSA in the detection and management of prostate cancer

Research output: Contribution to journalArticle

Abstract

Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Details

Authors
  • Kurt Miller
  • Per-Anders Abrahamsson
  • Koichiro Akakura
  • Frans M. J. Debruyne
  • Christopher P. Evans
  • Laurence Klotz
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Urology and Nephrology

Keywords

  • PSA doubling time, prostate cancer, PSA, PSA velocity
Original languageEnglish
Pages (from-to)327-333
JournalEuropean Urology. Supplement
Volume6
Issue number3
Publication statusPublished - 2007
Publication categoryResearch
Peer-reviewedYes